Jump to: navigation, search

Chronic myelomonocytic leukemia

54 bytes removed, 5 September
no edit summary
!style="width: 25%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
|[https://wwwdoi.natureorg/10.com1038/leu/journal/v28/n7/full/leu201485a.html 2014.85 Drummond et al. 2014]
|style="background-color:#91cf61"|Phase II
# Drummond MW, Pocock C, Boissinot M, Mills J, Brown J, Cauchy P, Cross NC, Hartley S, Kell J, Szubert A, Cockerill PN, Bowen DT. A multi-centre phase 2 study of azacitidine in chronic myelomonocytic leukaemia. Leukemia. 2014 Jul;28(7):1570-2. Epub 2014 Feb 26. [https://wwwdoi.natureorg/10.com1038/leu/journal/v28/n7/full/leu201485a.html 2014.85 link to original article] '''contains verified protocol''' [ PubMed]
# '''SWOG S1117:''' Sekeres MA, Othus M, List AF, Odenike O, Stone RM, Gore SD, Litzow MR, Buckstein R, Fang M, Roulston D, Bloomfield CD, Moseley A, Nazha A, Zhang Y, Velasco MR, Gaur R, Atallah E, Attar EC, Cook EK, Cull AH, Rauh MJ, Appelbaum FR, Erba HP. Randomized phase II study of azacitidine alone or in combination with lenalidomide or with vorinostat in higher-risk myelodysplastic syndromes and chronic myelomonocytic leukemia: North American Intergroup Study SWOG S1117. J Clin Oncol. 2017 Aug 20;35(24):2745-2753. Epub 2017 May 9. [ link to original article] '''contains verified protocol''' [ PubMed]
LookupUsers, editors, emailconfirmed, Administrators

Navigation menu